期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗体细胞因子融合蛋白治疗肿瘤的研究进展 被引量：1

Progress of Antibody-cytokine Fusion Proteins for the Therapy of Cancer
下载PDF
导出
摘要 抗体细胞因子融合蛋白保持了抗体和细胞因子两者的功能 ,能在肿瘤微环境浓集并直接增大抗体的抗肿瘤效应和 或宿主的抗肿瘤免疫。综述了IgG融合IL 2、GM CSF和IL 12融合蛋白的结构。 Antibody-cytokine fusion proteins retain both antibody and cytokine associated functions.These moleculars can concentrate the cytokine in the tumor microenvironment and in so doing directly enhance the tumoricidal effect of the antibody and/or enhance the host immune response against the tumor.This paper reviews the construction of several antibody-cytokine fusion proteins with IgG fused to the cytokine such as interleukin-2 (IL-2),granulocyte/macrophage colony-stimulating factor (GM-CSF),and interleukin-12 (IL-12),describes the properties of biology,and discusses the potential use in the treatment of human cancer.
作者 顾军 王雅杰
机构地区 解放军第 上海市长海医院肿瘤科
出处 《肿瘤防治杂志》 2003年第2期212-215,共4页 China Journal of Cancer Prevention and Treatment
关键词 抗体 生物因子 肿瘤 免疫学 重组融合蛋白质类 细胞因子 综述 antibody biological factor neoplasms/immunology recombination fusion proteins
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1[1]Rosenberg SA,Yang JC,White DE,et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2:identification of the antigens mediating response[J].Ann Surg,1998,228(3):307-319.
  • 2[2]Cohen J. IL-12 deaths:explanation and a puzzle[J].Science,1995,270(5238):908.
  • 3[3]Mass RA,Dullens HF,De Jong WH,et al. Immunotherapy of mice with a larg burden of disseminated lymphoma with low-dose interleukin-2[J].Cancer Res,1989,49(24):7037-7040.
  • 4[4]Soiffer R,Lynch T,Mihm M,et al. Vaccination with irradiated aut-ologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma[J].Pro Natl Acad Sci USA,1998,95(22):13141-13146.
  • 5[5]Hrouda D,Perry M,Dalagleish A G. Gene therapy for prostate cancer[J].Semin Oncol,1999,26(4):455-471.
  • 6[6]Grimm EA,Mazumder A,Zhang HZ,et al. Lymphokine-activated kille cell phenomenon.Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes[J].J Exp Med,1982,155(6):1823-1841.
  • 7[7]Roitt IM,Brostoff J,Male K(Eds). Immunology 2nd Edition[M].London:Gower Medical,1989.425-431.
  • 8[8]Harvill ET,Fleming JM,Morrison SL. An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit:real time measurement of ligand binding[J].Mol Immunol,1996,33(12):1007-1014.
  • 9[9]Mattijssen V,Balemans L,Steerenderg P A,et al. Plyethyene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors[J].Int J Cancer,1992,51(5):812-817.
  • 10[10]Peng LS,Penichet ML,Morrison SL. A single-chain IL-12 IgG3 anti-boby fusion protein retains antiboby specificity and IL-12 bioactivity and demonstrates antitumor activity[J].J Immumol,1999,163(1):250-258.

同被引文献12

  • 1胡云峰,洪斌,邵荣光.抗肿瘤基因工程单链抗体导向药物[J].中国生物工程杂志,2005,25(1):10-13. 被引量：5
  • 2Deeg HJ,Blazar BR,Bolwell BJ,et al.Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL [J].Blood,2001,98(7):2052.
  • 3Raffai R,Vukmirica J,Weisgraber KH,et al.Bacterial expression and purification of the Fab fragment of a monoclonal antibody specific for the low-density lipoprotein receptor-binding site of human apolipoprotein E[J].Protein Expr Purif,1999,16(1):84.
  • 4Sinha AA,Quast BJ,Reddy PK,et al.Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice[J].Anticancer Res,1999,19(2A):893.
  • 5Muyldermans S,Cambillau C,Wyns L.Recognition of antigens by single-domain antibody fragments:the superfluous luxury of paired domains[J].Trends Biochem Sci,2001,26(4):230.
  • 6Spooner RA,Murray S,Rowlinson-Busza G,et al.Geneti-cally engineered antibodies for diagnostic pathology[J].Hum Pathol,1994,25(6):606.
  • 7Thomas MB,Martin B,Michael G,et al.High-linear energy transfer(LET) versus low-let emitters in radioimmunotherapy of solid tumors:therapeutic efficacy and dose-limiting toxicity of labeled CO17-1Afragments in a human colonic cancer model[J].Cancer Res,1999,59(11):2635.
  • 8Penichet ML,Dela JS,Shin SU,et al.A recombinant Ig3-(IL-2) fusion protein for the treatment of human HERI/neu expressing tumors[J].Hum Antibodies,2001,10(1):43.
  • 9Kipriyanov SM,Moldenhauer G,Strauss G,et al.Bispecific CD3 CD19 diabody for T cell-mediated lysis of malignant human B cell[J].Int J Cancer,1998,77:763.
  • 10Arndt MAE,Krauss J,Kipriyanov SM,et al.A bispecific diabody that mediates natural killer cell cytotoxicity against xenotranspantate human Hodgkinstumors[J].Blood,1999,95:2562.

引证文献1

二级引证文献1

肿瘤防治杂志
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部